NCT01436526 - Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Therapeutic Equivalency

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)

Trial Locations (1)

41061

Mönchengladbach